Johnson & Johnson Nearing Deal to Buy Cancer Drug Maker Pharmacyclics

by Vishnuprasad on  March 6, 2015 at 7:58 PM Cancer News
RSS Email Print This Page Comment bookmark
Font : A-A+

The Financial Times on Wednesday reported that Johnson & Johnson is close to buying cancer drug maker Pharmacyclics Inc in the coming days.
 Johnson & Johnson Nearing Deal to Buy Cancer Drug Maker Pharmacyclics
Johnson & Johnson Nearing Deal to Buy Cancer Drug Maker Pharmacyclics

A bid from J&J is expected to value Pharmacyclics near its $17.5 billion market value or at a premium, FT said. Shares of Pharmacyclics, which markets blood cancer drug Imbruvica with J&J's Janssen unit, increased about 3 percent in extended trading.

Pharmacyclics has earlier said that sales of Imbruvica, which has U.S. approvals for four forms of blood cancer, are expected to touch $1 billion in the United States this year.

Bloomberg reported last month that Pharmacyclics was mulling a sale and had attracted the interest of J&J and Novartis AG. Any interest from J&J would be logical, considering its already established relationship with Pharmacyclics, experts in the industry said.



Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

Related Links

More News on:

Drug Toxicity Cancer and Homeopathy Signature Drug Toxicity Cancer Facts Cancer Tattoos A Body Art Oncology Drug Delivery Systems Common Lifestyle Habits that Cause Diseases Health Benefits of Dandelion Plant 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

Advertisement

News Category

News Archive